UT-MYHERITAGE
MyHeritage , den førende globale tjeneste til at opdage din fortid og tage kontrol over din fremtid, annoncerede i dag udgivelsen Deep Nostalgia™ , en ny funktion, der animerer ansigterne i stillbilleder. Deep Nostalgia™ giver slægtshistorien et helt nyt perspektiv ved at producere en realistisk skildring af, hvordan en person kunne have bevæget sig og set ud, hvis de blev fanget på video. MyHeritage er det eneste firma, der tilbyder en komplet pakke af funktioner til farvelægning, gendannelse, forbedring og nu animering af historiske fotos.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20210225005924/da/
Teknologien til animering af ansigterne på fotos blev licenseret af MyHeritage fra D-ID , et firma, der specialiserer sig i videogenskabelse ved hjælp af 'deep learning'. Deep Nostalgia™ bruger flere forindspillede driver-videoer udarbejdet af MyHeritage, som styrer bevægelserne i animationen og består af sekvenser af ægte menneskelige bevægelser. En foretrukken driver, baseret på dets retning, vælges automatisk for hvert ansigt, og anvendes derefter problemfrit på fotoet. Resultatet er en kort videoanimation i høj kvalitet af et ansigt, der kan smile, blinke og bevæge sig. For at opnå optimale resultater forbedres billederne inden animationen ved hjælp af MyHeritage Photo Enhancer , som giver slørede ansigter med lav opløsning fokus og øger deres opløsning.
Deep Nostalgia™ er det nyeste AI-baserede fotoværktøj på MyHeritage, og kommer i kølvandet på to meget roste funktioner, som virksomheden udgav sidste år, MyHeritage Photo Enhancer og MyHeritage In Color™ , der farvelægger sorte-hvide fotos og for nylig blev udvidet til også at gendanne farverne i falmede farvefotos. Disse funktioner er blevet virale og brugt over 30 millioner gange. MyHeritage fortsætter med at bygge på dette momentum ved at tilføje nye banebrydende værktøjer til historiske fotos, der inspirerer til en ny forståelse for slægtshistorie og nostalgiske familiefotos.
"Du oplever et 'wow-øjeblik', når du ser et værdsat familiefoto komme til live med Deep Nostalgia™”, sagde Gilad Japhet, grundlægger og administrerende direktør for MyHeritage. "At se vores elskede forfædres ansigter komme til live i en videosimulering giver os mulighed for at forestille os, hvordan de kunne have været i virkeligheden, og giver en helt ny måde at blive forbundet til vores slægtshistorie."
"Denne nye produktintegration er et spændende samarbejde mellem to innovative virksomheder," sagde Gil Perry, medstifter og administrerende direktør for D-ID. "Vi er begejstrede for, at vores teknologi vil være tilgængelig for millioner af mennesker på MyHeritage, og vi håber, at mange af dem vil nyde virkningen af videogenskabelse af historiske fotos."
Integration i MyHeritage-platformen
Deep Nostalgia™ er en freemium-funktion på MyHeritage. Brugere kan animere flere fotos gratis, uanset antallet af ansigter på billedet. Ud over det kræver fortsat brug et abonnement. Videoanimationen kan let deles med familie og venner på Facebook, Twitter, WhatsApp og andre sociale medier.
Om MyHeritage
MyHeritage er den førende globale platform til at opdage og udforske slægtshistorie. Med milliarder af historiske optegnelser og slægttræsprofiler og med sofistikerede matching-teknologier på tværs af alle dens aktiver, giver MyHeritage brugere mulighed for at opdage deres fortid og tage kontrol over deres fremtid. MyHeritage DNA er en af verdens største DNA-databaser med 4,7 millioner kunder. MyHeritage er den mest populære tjeneste for DNA-test og slægtsforskning i Europa. Siden 2020 er MyHeritage hjemsted for verdens bedste AI-teknologier til forbedring og farvelægning af historiske fotos. www.myheritage.dk
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210225005924/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum